Vortrag
Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
Speaker
Vortrag
Design of the Effect of EMPaglifozin on ExeRcise ability and HF-symptoms, In patients with chronic heArt faiLure (EMPERIAL) trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction
Autor:in